scorecardresearch
Monday, September 22, 2025
TopicSerum Institute of India

Topic: Serum Institute of India

Serum Institute of India gets govt nod to export 5 crore doses of Covovax to Indonesia

Covovax has been developed by Novavax and is being manufactured by the Pune-based SII, but is not cleared for emergency use in India.

Novavax’s Covid vaccine, made by Serum Institute of India, gets emergency use nod in Indonesia

Serum Institute of India, world's largest vaccine manufacturer, will market the nanoparticle protein-based vaccine in Indonesia under the brand name Covovax.

Vaccine makers upset over ‘differential pricing’ for ZyCov-D, and lack of clarity on exports

ZyCov-D has reportedly been priced by the company at Rs 1,900 for three doses while the others cost between Rs 205-215 per dose.

Biocon partners SII to make vaccine, drug manufacturing accessible to developing nations

Under the deal, Biocon Biologics Ltd (BBL) will offer approximately 15% stake to Serum Institute Life Sciences at a post-money valuation of about Rs 35,000 crore.

1 cr/day target achieved, Modi govt looks to administer 100 cr Covid vaccines in next 3 months

If projections of all four vaccine companies in India — SII, Zydus Cadila, Bharat Biotech and Biological E — are met, India is likely to acquire 100 crore more doses between October and December 2021.

Centre places order with Serum Institute of India for 66 crore Covishield doses

SII has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month, and the latest consignment ordered by Centre is to be supplied by December.

At 16.4 cr doses, SII’s increased Covishield output helps India cross Aug vaccination target

Modi govt, which projected 15 crore doses would be available in August, managed to achieve its 1 crore-doses-a-day plan last week. Meanwhile, Covaxin production lags.

Will supply 20 crore doses of Covishield in September, SII notifies Modi govt

In a production plan submitted to the Centre in May, SII’s director communicated that the production of Covishield would be ramped up to 10 crore each in August, September, said sources.

Serum Institute writes to Health Minister Mansukh Mandaviya to reform drug regulatory system

SII also sought permission to use the remaining quantities of batches of Covid and non-Covid vaccines for commercial purposes which have been used in the clinical trials.

SII to begin manufacturing Sputnik V in India by September, targets 300 million doses a year

Pune-based vaccine manufacturer SII has already received cell and vector samples for the production of Sputnik V from Russia's Gamaleya Center, the developer of the vaccine.

On Camera

1979 Mecca siege flashback—Saudi resorts to Pakistan to protect the Kingdom

Even though the Western media sometimes gives the impression that young Saudis overwhelmingly back Prince Salman’s efforts, some data suggest there is a deep pool of resentment.

Market regulator SEBI clears Adani Group of impropriety alleged by Hindenburg Research

SEBI probe concluded that purported loans and fund transfers were paid back in full and did not amount to deceptive market practices or unreported related party transactions.

60 yrs on, veterans recall lessons from 1965 India-Pakistan war. ‘Equipment alone doesn’t win battles’

A common thread runs through the memories of soldiers of the 1965 war—ingenuity, courage and camaraderie that withstood an apparently technologically superior foe.

India doesn’t give walkovers to Pakistan in war. Here’s why it shouldn’t do it in cricket either

Many really smart people now share the position that playing cricket with Pakistan is politically, strategically and morally wrong. It is just a poor appreciation of competitive sport.